匹多莫德佐治儿童大叶性肺炎支原体肺炎的疗效评价

董健; 吕响红; 刘伟; 江忠

doi:10.13898/j.cnki.issn.1000-2200.2018.03.022

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

匹多莫德佐治儿童大叶性肺炎支原体肺炎的疗效评价

董健 , 吕响红 , 刘伟 , 江忠

文章导航 > 蚌埠医学院学报 > 2018, 43 > 3: (355-357)

引用本文:

Citation:

匹多莫德佐治儿童大叶性肺炎支原体肺炎的疗效评价

山东省青岛市中心医院儿科, 266042

作者简介: 董健(1982-),女,住院医师.

通讯作者: 江忠, 副主任医师.jiangzhongfamily@163.com

中图分类号: R725.6

Effect of pidomode in the treatment of lobar Mycoplasma pneumoniae pneumonia in children

Department of Pediatric, Qingdao Central Hospital, Qingdao Shandong 266042, China

Corresponding author: JIANG Zhong, 副主任医师.jiangzhongfamily@163.com

CLC number: R725.6

摘要: 目的：观察匹多莫德佐治儿童大叶性肺炎支原体肺炎的临床效果，评价其对细胞免疫功能的影响。方法：选取48例大叶性MPP患儿随机分为A、B组，同时选取门诊同期体检的健康儿童30名为对照组。B组予以常规阿奇霉素（10 mg·kg^-1·d^-1，3个疗程）治疗，A组予以阿奇霉素联合匹多莫德（0.4 g/d，2个月）治疗，采用流式细胞仪检测对照组及A、B组患儿治疗前、治疗2个月后外周血T淋巴细胞亚群的变化，并且比较A、B组的临床效果。结果：治疗前，大叶性MPP组与对照组患儿血清CD3⁺、CD4⁺、CD4⁺/CD8⁺比例明显降低，CD8⁺比例升高（P<0.01）。治疗后，患儿血清CD3⁺、CD4⁺、CD4⁺/CD8⁺A组较治疗前明显升高（P<0.01）；B组较治疗前差异无统计学意义（P>0.05）；A组治疗后血清CD3⁺、CD4⁺、CD4⁺/CD8⁺较B组治疗后变化的差值差异有统计学意义（P<0.01），而血清CD8⁺2组治疗前、后差异均无统计学意义（P>0.05）。从治疗开始随访6个月，A组临床疗效明显优于B组（P<0.01）。结论：大叶性MPP患儿存在细胞免疫功能紊乱，匹多莫德可调节患儿免疫平衡，增强患儿的免疫力，提高临床。
- 大叶性肺炎支原体肺炎 /
- 儿童 /
- T淋巴细胞亚群
Abstract: Objective:To observe the clinical effects of pidomode in the treatment of lobar Mycoplasma pneumoniae pneumonia(MPP) in children,and evaluate its effect on cellular immune function.Methods:Forty-four children with lobar MPP were randomly divided into group A and group B,and 30 healthy children were set as control group.Group B were treated with azithromycin(10 mg·kg^-1·d^-1 each time) for 3 courses of treatmemt,and the group A were treated with azithromycin combined with pidotimod(0.4 g/d) for 2 months.The levels of T lymphocyte subsets in three group before treatment and after 2 months of treatment were detected using flow cytometry,and the clinical effect between group A and B was compared.Results:Before treatment,the serum levels of CD3⁺,CD4⁺ and CD4⁺/CD8⁺ in lobar MPP group significantly decreased,and the level of CD8⁺ increased compared with the control group(P<0.01).After treatment,the serum levels of CD3⁺,CD4⁺ and CD4⁺/CD8⁺ in group A significantly increased compared with before treatment(P<0.01),and the difference of which in group B between before and after treatment was not statistically significant(P>0.05).After treatment,the differences of the serum levels of CD3⁺,CD4⁺ and CD4⁺/CD8⁺ between group A and group B were statistically significant(P<0.01),and the difference of the level of serum CD8⁺ in two groups between before and after treatment was not statistically significant(P>0.05).From the beginning of treatment to follow for 6 months,the clinical curative effect in group A was better than that in group B(P<0.01).Conclusions:Cellular immune function disorder exists in lobar MPP,pidotimod can regulate the immune balance,strengthen immunity,and improve the clinical curative effect in children with lobar MPP.
- lobar Mycoplasma pneumoniae pneumonia /
- child /
- T lymphocyte subset

[1]	中华医学会儿科学分会呼吸学组,中华儿科杂志编辑委员会.儿童社区获得性肺炎管理指南(2013修订)(上)[J].中华儿科杂志,2013,51(10):745.
[2]	岳保珠,吴春莲,刘丽平.儿童肺炎支原体感染性大叶性肺炎10年发病研究[J].医学综述,2010,16(13):2071.
[3]	胡亚美,江载芳,诸福棠.实用儿科学[M].7版.北京:人民卫生出版社,2002:1204.
[4]	赵亮,刘洋.儿童重症肺炎支原体肺炎诊治进展[J].长江大学学报自然科学版:医学(下旬),2013,10(3):99.
[5]	朱美君,赵金华,赵晓冬,等.儿童肺炎支原体感染肺外并发症临床分析[J].齐鲁医学杂志,2015,30(1):47.
[6]	刘旭辉,朱虹,陈德利.支原体肺炎病儿体液免疫功能的动态变化[J].齐鲁医学杂志,2010,25(6):518.
[7]	LOENS K,GOOSSENS H,IEVEN M.Acute respiratory infection due to Mycoplasma pneumoniae:current status of diagnostic methods[J].Eur J Clin Microbiol Infect Dis,2010,29(9):1055.
[8]	NARITA M.Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special reference to pneumonia[J].J Infect Chemother,2010,16(3):162.
[9]	ROMERO-ROJAS A,REYES-ESPAR LA J,ESTRADA-PARRA S,et al.Immunomodulatory properties of Mycoplasma pulmonis.Ⅲ.Lympphocyte stimulation and cytokine production by mycoplasma pulmonis products[J].Int Immunopharmacol,2001,1(9/10):1699.
[10]	邓永洪,张荣贵,刘红霞,等.难治性肺炎支原体肺炎患儿免疫功能变化及匹多莫德免疫干预作用研究[J].河北医学,2015,21(6):920.
[11]	严永东.难治性肺炎支原体肺炎患儿免疫功能变化及匹多莫德的治疗作用[J].临床儿科杂志,2008,26(7):570.

[1]	王文雅 , 张秀敏 , 杜会双 , 徐敬梅 . 阿奇霉素对支原体肺炎患儿血清IgA、IgG、IgM水平及T淋巴细胞亚群的影响. 蚌埠医学院学报, 2016, 41(2): 175-177. doi: 10.13898/j.cnki.issn.1000-2200.2016.02.012
[2]	苗雨露 , 张明霞 . 重型颅脑损伤T淋巴细胞亚群的变化. 蚌埠医学院学报, 2015, 40(5): 624-626. doi: 10.13898/j.cnki.issn.1000-2200.2015.05.021
[3]	汪小五 , 丁圣刚 , 王林定 , 唐振华 , 朱义朗 , 高勇 . 儿童肺泡灌洗液肺炎支原体检出率及基因型分析. 蚌埠医学院学报, 2019, 44(1): 104-106. doi: 10.13898/j.cnki.issn.1000-2200.2019.01.029
[4]	刘安利 . 儿童支原体肺炎111例临床分析. 蚌埠医学院学报, 2013, 37(9): 1172-1174.
[5]	郭佳丽 , 茆康卫 , 杨自金 , 王娟 , 李红梅 , 陈刚 . 培土生金穴位敷贴对CVA患儿免疫球蛋白及T淋巴细胞亚群的影响. 蚌埠医学院学报, 2019, 44(8): 1084-1086. doi: 10.13898/j.cnki.issn.1000-2200.2019.08.030
[6]	李灿 , 郑蓉 . 帕瑞昔布钠超前镇痛对食管癌手术患者外周T淋巴细胞亚群分化的影响. 蚌埠医学院学报, 2013, 37(6): 684-687.
[7]	王勇 . 晚期恶性肿瘤患者化疗前后外周血T淋巴细胞亚群监测及临床意义. 蚌埠医学院学报, 2016, 41(11): 1452-1454. doi: 10.13898/j.cnki.issn.1000-2200.2016.11.014
[8]	梁友宝 , 梁华 , 李柏青 . 白介素-9产生细胞在不同淋巴细胞亚群中的比例. 蚌埠医学院学报, 2011, 36(5): 437-440.
[9]	汪珊 , 韦红 , 李启先 . 甲泼尼龙琥珀酸钠治疗儿童重症支原体肺炎的疗效及对炎症因子的影响. 蚌埠医学院学报, 2022, 47(1): 44-46. doi: 10.13898/j.cnki.issn.1000-2200.2022.01.011
[10]	卢玉振 . C反应蛋白检测在儿童支原体肺炎的诊断价值. 蚌埠医学院学报, 2011, 36(9): 958-959.
[11]	周宏媛 , 马莉娟 , 杨君 , 王娴娴 , 吴令琴 , 单子鸿 , 王舒颖 , 周瑞 . 两种剂量糖皮质激素在儿童难治性支原体肺炎中的疗效. 蚌埠医学院学报, 2020, 45(7): 891-894. doi: 10.13898/j.cnki.issn.1000-2020.07.013
[12]	张文婷 , 杨辉 , 蔡祥 . 血清降钙素原与超敏C反应蛋白及白细胞计数在儿童早期感染中的诊断价值. 蚌埠医学院学报, 2019, 44(11): 1508-1510. doi: 10.13898/j.cnki.issn.1000-2200.2019.11.020
[13]	耿松乔 , 马晓燕 , 刘杰 . 呼吸道感染儿童呼吸道病原体检测分析. 蚌埠医学院学报, 2018, 43(5): 603-605. doi: 10.13898/j.cnki.issn.1000-2200.2018.05.011
[14]	孔少云 , 程正平 , 李晓春 , 乐嘉东 , 王飞 . 小儿肺炎支原体感染82例临床分析. 蚌埠医学院学报, 2005, 30(5): 427-429.
[15]	马进 . 小儿肺炎支原体肺炎肺外并发症23例临床分析. 蚌埠医学院学报, 2005, 30(6): 536-537.
[16]	薛丽芬 . 无锡市蠡湖社区7岁以下儿童5年体格检查结果分析. 蚌埠医学院学报, 2010, 35(12): 1300-1301.
[17]	苏国德 , 武怡 , 屈昌雪 . 450例重症社区获得性肺炎患儿痰液病原体分布及细菌耐药特点. 蚌埠医学院学报, 2019, 44(11): 1477-1480, 1483. doi: 10.13898/j.cnki.issn.1000-2200.2019.11.011
[18]	吴向英 . 年长儿和婴幼儿支原体肺炎的临床特征对比分析. 蚌埠医学院学报, 2014, 39(9): 1233-1235.
[19]	陈贞祥 , 沈怀云 , 诸宏伟 , 董淮富 . 雾化吸入布地奈德、硫酸特布他林佐治小儿重症肺炎30例. 蚌埠医学院学报, 2011, 36(5): 467-469.
[20]	邱敏 , 季然 . 传染性单核细胞增多症患儿60例临床观察. 蚌埠医学院学报, 2017, 42(8): 1083-1086. doi: 10.13898/j.cnki.issn.1000-2200.2017.08.022

点击查看大图

计量

文章访问数: 3746
HTML全文浏览量: 472
PDF下载量: 35
被引次数: 0

匹多莫德佐治儿童大叶性肺炎支原体肺炎的疗效评价

通讯作者: 江忠, 副主任医师.jiangzhongfamily@163.com

作者简介: 董健(1982-),女,住院医师.

山东省青岛市中心医院儿科, 266042

收稿日期: 2016-07-29
录用日期: 2017-11-29

关键词:

摘要: 目的：观察匹多莫德佐治儿童大叶性肺炎支原体肺炎的临床效果，评价其对细胞免疫功能的影响。方法：选取48例大叶性MPP患儿随机分为A、B组，同时选取门诊同期体检的健康儿童30名为对照组。B组予以常规阿奇霉素（10 mg·kg^-1·d^-1，3个疗程）治疗，A组予以阿奇霉素联合匹多莫德（0.4 g/d，2个月）治疗，采用流式细胞仪检测对照组及A、B组患儿治疗前、治疗2个月后外周血T淋巴细胞亚群的变化，并且比较A、B组的临床效果。结果：治疗前，大叶性MPP组与对照组患儿血清CD3⁺、CD4⁺、CD4⁺/CD8⁺比例明显降低，CD8⁺比例升高（P<0.01）。治疗后，患儿血清CD3⁺、CD4⁺、CD4⁺/CD8⁺A组较治疗前明显升高（P<0.01）；B组较治疗前差异无统计学意义（P>0.05）；A组治疗后血清CD3⁺、CD4⁺、CD4⁺/CD8⁺较B组治疗后变化的差值差异有统计学意义（P<0.01），而血清CD8⁺2组治疗前、后差异均无统计学意义（P>0.05）。从治疗开始随访6个月，A组临床疗效明显优于B组（P<0.01）。结论：大叶性MPP患儿存在细胞免疫功能紊乱，匹多莫德可调节患儿免疫平衡，增强患儿的免疫力，提高临床。

English Abstract

Effect of pidomode in the treatment of lobar Mycoplasma pneumoniae pneumonia in children

Corresponding author: JIANG Zhong, 副主任医师.jiangzhongfamily@163.com

Department of Pediatric, Qingdao Central Hospital, Qingdao Shandong 266042, China

Received Date: 2016-07-29
Accepted Date: 2017-11-29

Abstract: Objective:To observe the clinical effects of pidomode in the treatment of lobar Mycoplasma pneumoniae pneumonia(MPP) in children,and evaluate its effect on cellular immune function.Methods:Forty-four children with lobar MPP were randomly divided into group A and group B,and 30 healthy children were set as control group.Group B were treated with azithromycin(10 mg·kg^-1·d^-1 each time) for 3 courses of treatmemt,and the group A were treated with azithromycin combined with pidotimod(0.4 g/d) for 2 months.The levels of T lymphocyte subsets in three group before treatment and after 2 months of treatment were detected using flow cytometry,and the clinical effect between group A and B was compared.Results:Before treatment,the serum levels of CD3⁺,CD4⁺ and CD4⁺/CD8⁺ in lobar MPP group significantly decreased,and the level of CD8⁺ increased compared with the control group(P<0.01).After treatment,the serum levels of CD3⁺,CD4⁺ and CD4⁺/CD8⁺ in group A significantly increased compared with before treatment(P<0.01),and the difference of which in group B between before and after treatment was not statistically significant(P>0.05).After treatment,the differences of the serum levels of CD3⁺,CD4⁺ and CD4⁺/CD8⁺ between group A and group B were statistically significant(P<0.01),and the difference of the level of serum CD8⁺ in two groups between before and after treatment was not statistically significant(P>0.05).From the beginning of treatment to follow for 6 months,the clinical curative effect in group A was better than that in group B(P<0.01).Conclusions:Cellular immune function disorder exists in lobar MPP,pidotimod can regulate the immune balance,strengthen immunity,and improve the clinical curative effect in children with lobar MPP.